

# **Evaluation Cosmetic Outcome In Stage I And II Breast Carcinoma After Conservative Treatment**

## **Essay**

Submitted For Partial Fulfillment of Master Degree  
in **Clinical Oncology and Nuclear Medicine**

**By**

**Lamiaa Moustafa Abdel Megied Mohamed**

*M.B.,B.Ch*

**Under Supervision of**

**Prof.Dr. Iman Aly El Sharawy**

**Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine, Ain Shams University**

**Dr. Dina Ahmed Mohamed Salem**

**Assistant Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine, Ain Shams University**

**Dr. Mai Mohamed Ali Ezz EL Deen**

**Lecturer of Clinical Oncology and Nuclear medicine  
Faculty of Medicine, Ain Shams University**

**Faculty of Medicine  
Ain Shams University**

**2013**

## بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

(...رَبِّ أَوْزَعْنِي أَنْ أَشْكُرَ نِعْمَتَكَ  
الَّتِي أَنْعَمْتَ عَلَيَّ وَ عَلَى وَالِدَيَّ  
وَأَنْ أَعْمَلَ صَالِحاً تَرْضَاهُ وَ أَدْخِلْنِي  
بِرَحْمَتِكَ فِي عِبَادِكَ الصَّالِحِينَ)

## صدق الله العظيم

النمل.. آية رقم 19



## Acknowledgement

*First and foremost, I thank **Allah** who gave me the strength to fulfill this work.*

*I would like to express my sincere gratitude to **Prof. Dr. Iman Aly El Sharawy**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her kind supervision, encouragement and constant help. I have the honor to complete this work under her supervision.*

*I am grateful to **Dr. Dina Ahmed Mohamed Salem**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his constant supervision and honest assistance. His moral support cannot be praised enough with words.*

*It is a great honor to express my sincere appreciation to **Dr. Mai Mohamed Ali Ezz El Deen**, Lecturer of Clinical Oncology and Nuclear medicine, Faculty of Medicine, Ain Shams University, for her kind supervision, continuous encouragement and persistent support, her valuable advice helped me complete this work.*

**Lamiaa Moustafa Abdel Megied Mohamed**



*I would like to dedicate this Essay*

*To my Father, to my Mother*

*To my Brother to my Sister*

*and To my Husband*

*To them I will never find adequate words  
to express my gratitude.*

# List of Contents

| Subject                                                    | Page No.                     |
|------------------------------------------------------------|------------------------------|
| List of Abbreviations .....                                | i                            |
| List of Tables .....                                       | iii                          |
| List of Figures.....                                       | iv                           |
| Introduction.....                                          | 1                            |
| Aim of the Work.....                                       | 7                            |
| Chapter (1): Epidemiology and Risk factors                 | Error! Bookmark not defined. |
| Chapter (2): Histopathology.....                           | 23                           |
| Chapter (3): Molecular Biology .....                       | 35                           |
| Chapter (4): Diagnosis and Staging.....                    | 47                           |
| Chapter (5): Treatment of Invasive Bladder<br>Cancer ..... | 64                           |
| Summary.....                                               | 117                          |
| References.....                                            | 122                          |
| Arabic Summary .....                                       | —                            |

---

## List of Abbreviations

---

|                |                                                              |
|----------------|--------------------------------------------------------------|
| <b>ABC</b>     | : Advanced Bladder cancer meta-analysis collaboration        |
| <b>AJCC</b>    | : American Joint Committee on Cancer                         |
| <b>ATP</b>     | : Adenosine triphosphate                                     |
| <b>BC</b>      | : Bladder cancer                                             |
| <b>BT</b>      | : Brachytherapy                                              |
| <b>CALGB</b>   | : Current Cancer and Leukemia Group B                        |
| <b>CBC</b>     | : Complete blood count                                       |
| <b>CIS</b>     | : Carcinoma in situ                                          |
| <b>cIScA</b>   | : Cisplatin, cyclophosphamide, and adriamycine               |
| <b>CM</b>      | : Cyclophosphamide - methotrexate                            |
| <b>CMV</b>     | : Cyclophosphamide - methotrexate – vincristine              |
| <b>CT</b>      | : Computed tomography                                        |
| <b>CTV</b>     | : Clinical Target Volume                                     |
| <b>EAU</b>     | : European Association of Urology                            |
| <b>EBrT</b>    | : External beam radiation therapy                            |
| <b>ECOG</b>    | : Eastern Cooperative Oncology Group                         |
| <b>EGFR</b>    | : Epidermal growth factor receptor                           |
| <b>EorTc</b>   | : European Organization for research and Treatment of cancer |
| <b>ESMO</b>    | : European Society for Medical Oncology                      |
| <b>FAcT</b>    | : Functional Assessment of cancer Therapy                    |
| <b>FDG-PET</b> | : Fluorodeoxyglucose -positron emission tomography           |
| <b>FISH</b>    | : Florescence in suit hybridization                          |
| <b>GC</b>      | : Gemcitabine,Cisplatin                                      |
| <b>Gy</b>      | : Gray                                                       |
| <b>hAL</b>     | : Hexaminolaevulinate                                        |
| <b>hrQoL</b>   | : Health-related quality of life                             |
| <b>IArc</b>    | : International Agency for research on cancer                |
| <b>IHC</b>     | : Immunohistochemistry                                       |
| <b>mAbs</b>    | : Monoclonal antibodies                                      |
| <b>MIBC</b>    | : Muscle-invasive bladder cancer                             |
| <b>MRI</b>     | : Magnetic resonance imaging                                 |

---

---

## **List of Abbreviations (*Cont...*)**

---

|                |                                                                       |
|----------------|-----------------------------------------------------------------------|
| <b>MVA(E)c</b> | : Methotrexate-vincristine- adriamycin (epirubicin) -cyclophosphamide |
| <b>NCCN</b>    | : National Comprehensive Cancer Network                               |
| <b>NcI</b>     | : National cancer Institute                                           |
| <b>NmIBc</b>   | : Non-muscle invasive bladder cancer                                  |
| <b>OAR</b>     | : Organ at risk                                                       |
| <b>PAHs</b>    | : Polycyclic aromatic hydrocarbons                                    |
| <b>PFS</b>     | : Progression free survival                                           |
| <b>Ps</b>      | : Performance status                                                  |
| <b>PTV</b>     | : Planning target volume                                              |
| <b>PUNLMP</b>  | : Papillary urothelial neoplasms of low malignant potential           |
| <b>RALC</b>    | : Robotic-assisted laparoscopic cystectomy                            |
| <b>Rb</b>      | : Retinoblastoma gene                                                 |
| <b>rP</b>      | : Radical prostatectomy                                               |
| <b>RTKs</b>    | : Receptor tyrosine kinases                                           |
| <b>RTOG</b>    | : Radiation Therapy Oncology Group                                    |
| <b>SCCs</b>    | : Squamous cell carcinomas                                            |
| <b>SEER</b>    | : Surveillance, Epidemiology and End Results                          |
| <b>SES</b>     | : Socioeconomic status                                                |
| <b>SWOG</b>    | : Southwest Oncology Group                                            |
| <b>TCC</b>     | : Transitional cell carcinoma                                         |
| <b>TKI</b>     | : Tyrosine receptor kinase inhibitors                                 |
| <b>TNM</b>     | : Tumor,node,metastasis                                               |
| <b>TUR</b>     | : Transurethral resection                                             |
| <b>TURBT</b>   | : Transurethral resection of bladder tumor                            |
| <b>URCa</b>    | : Urothelial carcinoma                                                |
| <b>US</b>      | : Ultrasonography                                                     |
| <b>VEGF</b>    | : Vascular endothelial growth factor                                  |
| <b>WHO</b>     | : World Health Organization                                           |
| <b>3-D</b>     | : three - Dimensional                                                 |
| <b>4-ABP</b>   | : 4-aminobiphenyl                                                     |
| <b>5-ALA</b>   | : 5-aminolevulinic acid                                               |
| <b>5-FU</b>    | : 5-fluorouracil                                                      |

---

# List of Tables

| Table No.         | Title                                                                                                                                                | Page No. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| <b>Table (1):</b> | WHO 2004 Histologic Classification of Tumors of the Urinary Bladder .....                                                                            | 31       |
| <b>Table (2):</b> | Histologic Patterns of Lamina Propria Invasion.....                                                                                                  | 33       |
| <b>Table (3):</b> | Established clinicopathologic and potential molecular prognostic parameters in superficial and muscle invasive urothelial carcinoma of bladder ..... | 38       |
| <b>Table (4):</b> | American Joint Committee on Cancer (AJCC) TNM Staging System for Bladder Cancer .....                                                                | 60       |
| <b>Table (5):</b> | AJCC Stage Groups.....                                                                                                                               | 61       |
| <b>Table (6):</b> | Most common complication of radical cystectomy .....                                                                                                 | 69       |
| <b>Table (7):</b> | Randomized phase 3 trials of neoadjuvant chemotherapy.....                                                                                           | 90       |
| <b>Table (8):</b> | Adjuvant chemotherapy trials following cystectomy .....                                                                                              | 106      |

# List of Figures

| Figure No.         | Title                                                                                                                                                        | Page No. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| <b>Figure (1):</b> | Incidence & Mortality rate of bladder cancer .....                                                                                                           | 10       |
| <b>Figure (2):</b> | Urothelial carcinoma with squamous differentiation and keratinization .....                                                                                  | 26       |
| <b>Figure (3):</b> | Squamous cell carcinoma associated with Schistosomiasis shows a well-differentiated squamous cell carcinoma (arrow) infiltrating the muscularis propria..... | 28       |
| <b>Figure (4):</b> | High-grade urothelial carcinoma invasive into adipose tissue in muscularis propria .....                                                                     | 30       |
| <b>Figure (5):</b> | Urothelial carcinoma, nested variant: Closely packed nests of urothelial cells with bland cytological features .....                                         | 30       |
| <b>Figure (6):</b> | Urothelial carcinoma, giant cell variant.....                                                                                                                | 30       |
| <b>Figure (7):</b> | Sarcomatoid variant of urothelial carcinoma, heterologous type, with malignant cartilage .....                                                               | 30       |
| <b>Figure (8):</b> | Divergent molecular pathways of oncogenesis in superficial and muscle invasive urothelial carcinoma of urinary bladder.....                                  | 36       |
| <b>Figure (9):</b> | Axial CT image of the bladder shows a large urothelial carcinoma. There is irregular soft-tissue stranding from tumor invasion into the perivesical.....     | 51       |

## **List of Figures (Cont...)**

| <b>Figure No.</b>   | <b>Title</b>                                                                                                     | <b>Page No.</b> |
|---------------------|------------------------------------------------------------------------------------------------------------------|-----------------|
| <b>Figure (10):</b> | CT urography images show mild asymmetric thickening of anterior bladder wall.....                                | 52              |
| <b>Figure (11):</b> | Invasive urothelial carcinoma. Axial gadolinium-enhanced fat-suppressed T1-weighted MR image of the bladder..... | 54              |
| <b>Figure (12):</b> | Longitudinal US image of the bladder shows a large, hypoechoic urothelial carcinoma within the bladder .....     | 55              |
| <b>Figure (13):</b> | T staging in bladder cancer .....                                                                                | 61              |
| <b>Figure (14):</b> | Difference of overall survival between M-VAC+Cystectomy and Cystectomy alone.....                                | 84              |
| <b>Figure (15):</b> | Anterior–posterior and lateral RT fields in bladder cancer.....                                                  | 97              |
| <b>Figure (16):</b> | CT axial slice with Clinical target volume whole bladder, Planning Target Volume and Organ at risk. Rectum.....  | 98              |
| <b>Figure (17):</b> | Axial CT slice showing conformal plan for whole bladder irradiation.....                                         | 98              |
| <b>Figure (18):</b> | Schema for trimodality treatment invasive bladder cancer with selective bladder preservation .....               | 103             |
| <b>Figure (19):</b> | Flowchart on the management for T2-T3 N0M0 urothelial bladder cancer .....                                       | 107             |



## Introduction

Bladder cancer is a common urologic cancer. In 2010, the urinary bladder was the fourth most common site of new cancer cases in the United States, with an estimated 70,530 new cases and 14,680 deaths. More than 60,000 new cases of bladder cancer are diagnosed each year in the United States. It is more common in men, with a male: female ratio of 4:1 (*Jemal et al., 2010*).

Age appears to increase the risk; the median age upon presentation with bladder cancer is 72 years for men and 74 years for women (*Jacobs et al., 2010*).

In developed countries, 90% of bladder cancers are Transitional cell carcinoma (TCC). In developing countries—particularly in the Middle East and Africa—the majority of bladder cancers are squamous cell carcinomas (SCCs), and most of these cancers are secondary to *Schistosoma haematobium* infection (*Steinberg, 2013*).

In Africa, the highest incidence of SCC has been seen in schistosoma-endemic areas, notably Sudan and Egypt. In recent years, a few studies from Egypt have shown a reversal of this trend due to the better control of schistosomiasis in the region, whereas in other parts of Africa the association is unchanged (*Heyns et al., 2008*). Increased smoking incidence is

believed to have contributed to the shift toward TCC in Egypt, which has a stronger smoking association (**Steinberg, 2013**).

A number of etiological factors are associated with the development of bladder cancer such as chronic urinary infection, pelvic Radiation, chemotherapy with cyclophosphamide and occupational exposure to aromatic amines. However Cigarette smoking is the largest risk factor for bladder cancer (**Jacobs et al., 2010**).

**Clinically**, Hematuria is the hallmark sign of bladder cancer, occurring in 85% of patients at presentation. Increased urinary frequency and dysuria may also be presenting symptom. More advanced disease may present with pelvic pain and all the symptoms of urinary obstruction (**Stenzl et al., 2010**).

The American Joint Committee on Cancer TNM (primary tumor, regional lymph nodes, and distant metastasis) Staging System is used for staging bladder cancer. Correct staging can estimate the prognosis and risk of recurrence and is used to determine treatment strategies. Under staging, a common problem may result in incorrect treatment decisions (**Kulkarni et al., 2010**). There is a 10% chance that a high-grade Ta or T1 lesion is really muscle-invasive disease (**Babjuk et al., 2010**).

Muscle-invasive bladder cancer (clinical stage cT2-cT4a) is an aggressive epithelial tumor with a high rate of early

systemic dissemination and 5-year survival depending principally on pathologic stage and nodal status. Although only one-third of the newly diagnosed bladder cancers are advanced at presentation, another 15–30% of high-grade superficial tumors progress to muscle-invasive tumors, usually within 5 yr (**Fabio and Cora, 2008**).

The gold standard for diagnosis is cystoscopy. Intraurethral lidocaine is used to perform this procedure, in which abnormal tissue is resected. This resection is called *transurethral resection of bladder tumor* (TURBT) (**Babjuk et al., 2010**). Urinary cytology is an important adjunct to cystoscopy and is helpful for identifying high-grade tumors, such as carcinoma in situ (CIS). The presence of exfoliated cancerous cells can indicate cancer anywhere along the urinary tract, and the absence of cancer cells does not rule out the presence of a low-grade lesion (**Sexton et al., 2010**).

CT and MRI may be used to determine the stage of bladder cancer; however, they are unable to accurately detect early metastatic disease. Ultrasonography is being used more frequently and is advantageous because it does not require contrast agent (**Babjuk et al., 2010**). Another imaging modality is IV urography. If invasive disease is suspected, diagnostic imaging should be done prior to TURBT because inflammation from TURBT can be impossible to distinguish from tumor growth in the perivesical fat (**Suzanne et al., 2011**).

Approximately one-third of patients diagnosed with muscle-invasive bladder cancer have metastatic disease at the time that the first tumor is treated (**Stenzl et al., 2010**). It is important to determine the presence of distant metastasis prior to treatment selection. The most common sites of metastasis are the lungs, bones, and liver (**Jacobs et al., 2010**).

TURBT performed during cystoscopy is a treatment as well as diagnostic tool. All visible lesions should be removed, along with muscle tissue, to ensure complete resection and proper staging (**Pharmd et al., 2011**). For localized muscle-invasive disease, radical cystectomy is the standard treatment. Although it is desirable to preserve the bladder, delaying radical cystectomy is thought to increase the risk of lymph node metastasis by 26% (**Mslis et al., 2011**).

Neoadjuvant therapy administering chemotherapy prior to radical cystectomy can help determine the sensitivity of the carcinoma to the selected chemotherapeutic agents. Other advantages include better patient tolerability to chemotherapy prior to radical cystectomy and delivery of therapy at the earliest time, when occurrence of micrometastatic disease is expected to be low. Among the disadvantages associated with the use of neoadjuvant are staging errors and overtreatment (**Suzanne et al., 2010**). Chemotherapy should include a cisplatin-containing regimen, either MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) or GC (gemcitabine and cisplatin). Neither

combination has been shown to be superior to the other; However, GC is less toxic (*Sonpavde et al., 2010*).

The use of adjuvant chemotherapy postoperatively has not been shown to have a benefit. Additionally, patients often cannot tolerate systemic chemotherapy after radical cystectomy. The European Association of Urology (EAU) guidelines recommend adjuvant therapy for clinical trials, but not for routine use (*Cowan et al., 2010*).

Bladder -preserving approaches are reasonable alternatives to cystectomy for patients who are medically unfit for surgery and those seeking an alternative (*National Comprehensive Cancer Network (NCCN), 2013*).

A trimodality treatment approach for muscle-invasive bladder cancer consists of transurethral resection (TUR) for the primary tumor followed by a combination of local radiation therapy and systemic chemotherapy (*Weiss et al., 2006*).

Radiation alone is not considered standard treatment for patients with an invasive bladder tumor. Because the initial complete response and long-term bladder preservation rates are higher with chemotherapy combined with radiotherapy (*Gospodarowicz, 2000*).

Antiangiogenic therapy is under investigation as second-line therapy (*Bellmunt et al., 2010*). Vascular endothelial growth factor (VEGF) is the most important stimulator of

---